Venrock Healthcare Capital Partners II, L.P.

Venrock Healthcare Capital Partners II, L.P. discloses dealings in 4 companies, chiefly Tricida, Inc., Adverum Biotechnologies, Inc. and KalVista Pharmaceuticals, Inc. The record holds 53 filings, for trades running from 5 August 2014 to 26 October 2022.

In open-market terms, that means 47 purchases worth €51.4M on one side and 5 sales worth €16.3M on the other. On balance, insiders were net buyers of €35.1M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2022: 46 purchases and 4 sales on the market.

A typical purchase (the median) is worth €513k. No cluster: in 46 purchases, no other insider of the company bought within 30 days.

Most recently, on 26 October 2022, the filings show an open-market sale worth €1.1M in Tricida, Inc. The clock since the last published purchase (20 October 2022) now reads 1,466 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.